Profile data is unavailable for this security.
About the company
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
- Revenue in EUR (TTM)238.28m
- Net income in EUR-189.73m
- Incorporated1998
- Employees524.00
- LocationMorphoSys AGSemmelweisstr. 7PLANEGG 82152GermanyDEU
- Phone+49 89899270
- Fax+49 8 989927222
- Websitehttps://www.morphosys.com
Holder | Shares | % Held |
---|---|---|
Kynam Capital Management LPas of 13 Mar 2024 | 4.19m | 11.13% |
Goldman Sachs & Co. LLC (Private Banking)as of 29 Feb 2024 | 4.14m | 11.00% |
Adage Capital Management LPas of 22 Jan 2024 | 1.89m | 5.02% |
DWS Investment GmbHas of 18 Mar 2024 | 1.52m | 4.03% |
RP Management LLC (Investment Management)as of 16 Feb 2024 | 1.34m | 3.55% |
The Vanguard Group, Inc.as of 07 Mar 2024 | 1.25m | 3.32% |
Caligan Partners LPas of 28 Feb 2023 | 1.06m | 2.81% |
Baillie Gifford & Co.as of 16 Dec 2022 | 835.29k | 2.22% |
BlackRock Fund Advisorsas of 07 Mar 2024 | 462.54k | 1.23% |
Norges Bank Investment Managementas of 31 Dec 2023 | 459.29k | 1.22% |